Your browser is no longer supported. Please, upgrade your browser.
Brooklyn ImmunoTherapeutics, Inc.
Index- P/E- EPS (ttm)-2.38 Insider Own11.40% Shs Outstand50.54M Perf Week8.20%
Market Cap340.78M Forward P/E- EPS next Y-0.50 Insider Trans-6.77% Shs Float24.65M Perf Month-35.15%
Income-113.60M PEG- EPS next Q- Inst Own9.80% Short Float2.81% Perf Quarter-50.71%
Sales1.20M P/S283.98 EPS this Y-110.90% Inst Trans13.35% Short Ratio1.08 Perf Half Y-59.73%
Book/sh0.26 P/B22.85 EPS next Y- ROA-353.30% Target Price20.00 Perf Year38.14%
Cash/sh0.43 P/C13.97 EPS next 5Y- ROE- 52W Range3.59 - 80.67 Perf YTD32.59%
Dividend- P/FCF- EPS past 5Y17.40% ROI-217.30% 52W High-92.64% Beta4.67
Dividend %- Quick Ratio5.60 Sales past 5Y-25.00% Gross Margin53.80% 52W Low65.46% ATR0.57
Employees22 Current Ratio5.60 Sales Q/Q- Oper. Margin- RSI (14)36.18 Volatility9.34% 8.81%
OptionableYes Debt/Eq0.03 EPS Q/Q-68.80% Profit Margin- Rel Volume0.89 Prev Close5.87
ShortableYes LT Debt/Eq0.00 EarningsNov 09 AMC Payout- Avg Volume639.02K Price5.94
Recom- SMA20-13.14% SMA50-27.31% SMA200-52.44% Volume568,050 Change1.19%
Oct-06-21Initiated Maxim Group Buy $20
Dec-02-21 08:00AM  
Nov-29-21 08:00AM  
Nov-19-21 06:00AM  
Nov-09-21 04:35PM  
Oct-27-21 07:05AM  
Oct-14-21 04:15PM  
Oct-07-21 10:11PM  
Sep-23-21 04:30PM  
Sep-22-21 10:07AM  
Sep-21-21 08:30AM  
Sep-15-21 08:15AM  
Sep-13-21 08:00AM  
Sep-09-21 08:30AM  
Aug-20-21 04:15PM  
Aug-16-21 04:15PM  
Aug-13-21 02:22PM  
Jul-23-21 04:30PM  
Jul-19-21 08:00AM  
Jul-13-21 08:15AM  
Jul-12-21 08:15AM  
Jul-08-21 11:20AM  
Jul-06-21 05:57PM  
Jun-14-21 07:30AM  
Jun-09-21 07:30AM  
Jun-08-21 07:30AM  
Jun-02-21 08:00AM  
May-26-21 02:03PM  
May-24-21 02:58PM  
May-21-21 07:30AM  
May-18-21 07:30AM  
May-11-21 07:30AM  
May-07-21 07:30AM  
Apr-29-21 07:30AM  
Apr-26-21 07:30AM  
Apr-19-21 04:10PM  
Apr-15-21 04:10PM  
Apr-06-21 08:00AM  
Mar-25-21 05:20PM  
Dec-14-20 08:44AM  
Nov-04-20 06:05PM  
May-08-20 10:37PM  
Brooklyn ImmunoTherapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing therapies to treat patients with cancer. Its advanced program is IRX-2 that is in a Phase 2b clinical trial in patients with squamous cell cancer of the head and neck. The company is based in Brooklyn, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
DENNY GEORGE P III10% OwnerJul 14Buy11.991123Aug 20 01:38 PM
DENNY GEORGE P III10% OwnerJul 09Buy14.111142Aug 20 01:38 PM
DENNY GEORGE P III10% OwnerJul 08Buy14.351141Aug 20 01:38 PM
DENNY GEORGE P III10% OwnerJul 06Sale16.0675,0001,204,6884,775,117Aug 20 01:38 PM
Cherington CharlesDirectorJun 17Sale15.75200,0003,149,8085,894,101Jun 21 06:00 PM
Cherington CharlesDirectorJun 16Sale15.73200,0003,146,7606,094,101Jun 21 06:00 PM